ReviewStem cells international2017
A Molecular and Clinical Review of Stem Cell Therapy in Critical Limb Ischemia.
Review in Stem cells international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 41 citations in OpenAlex.
- Evaluation of safety and efficacy: a case series of chronic limb-threatening ischemia treated with endovascular revascularization and umbilical cord mesenchymal stem cell therapy.Stem cell research & therapy · 2025Review
- Article
- Therapeutic effect and study of human umbilical cord blood mononuclear cells in patients with ischaemic bowel disease.Scientific reports · 2024Article
- Cell Therapy of Severe Ischemia in People with Diabetic Foot Ulcers-Do We Have Enough Evidence?Molecular diagnosis & therapy · 2023Article
- Report of a phase 1 clinical trial for safety assessment of human placental mesenchymal stem cells therapy in patients with critical limb ischemia (CLI).Stem cell research & therapy · 2023Article
- Stem Cell Therapy in Critical Limb Ischemia.Cureus · 2023Review
- Mesenchymal stem cell-based therapy for non-healing wounds due to chronic limb-threatening ischemia: A review of preclinical and clinical studies.Frontiers in cardiovascular medicine · 2023Review
- Emerging roles of mesenchymal stem cell therapy in patients with critical limb ischemia.Stem cell research & therapy · 2022Review
- Efficient generation of endothelial cells from induced pluripotent stem cells derived from a patient with peripheral arterial disease.Cell and tissue research · 2022Article
- Mesenchymal Stem Cells Regenerate Diabetic Foot Ulcers: A Review Article.World journal of plastic surgery · 2022Review
- Stem Cell-Based Therapies: What Interventional Radiologists Need to Know.Seminars in interventional radiology · 2021Review
- Autologous cell therapy in diabetes‑associated critical limb ischemia: From basic studies to clinical outcomes (Review).International journal of molecular medicine · 2021Review
- Cell Therapy for Critical Limb Ischemia: Advantages, Limitations, and New Perspectives for Treatment of Patients with Critical Diabetic Vasculopathy.Current diabetes reports · 2021Review
- Bioengineering strategies for the treatment of peripheral arterial disease.Bioactive materials · 2021Review
- E-Selectin-Overexpressing Mesenchymal Stem Cell Therapy Confers Improved Reperfusion, Repair, and Regeneration in a Murine Critical Limb Ischemia Model.Frontiers in cardiovascular medicine · 2021Article
- N-acetylcysteine differentially regulates the populations of bone marrow and circulating endothelial progenitor cells in mice with limb ischemia.European journal of pharmacology · 2020Article
- Collateral Development and Arteriogenesis in Hindlimbs of Swine After Ligation of Arterial Inflow.The Journal of surgical research · 2020Article
- Increasing the Therapeutic Potential of Stem Cell Therapies for Critical Limb Ischemia.HSOA journal of stem cells research, development & therapy · 2020Article
- Transplantation of Adipose Stromal Cell Sheet Producing Hepatocyte Growth Factor Induces Pleiotropic Effect in Ischemic Skeletal Muscle.International journal of molecular sciences · 2019Article
- Concomitant overexpression of triple antioxidant enzymes selectively increases circulating endothelial progenitor cells in mice with limb ischaemia.Journal of cellular and molecular medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peripheral artery disease (PAD) is one of the major vascular complications in individuals suffering from diabetes and in the elderly that can progress to critical limb ischemia (CLI), portending significant burden in terms of patient morbidity and mortality. Over the last two decades, stem cell therapy (SCT) has risen as an attractive alternative to traditional surgical and/or endovascular revascularization to treat this disorder. The primary benefit of SCT is to induce therapeutic neovascularization and promote collateral vessel formation to increase blood flow in the ischemic limb and soft tissue. Existing evidence provides a solid rationale for ongoing in-depth studies aimed at advancing current SCT that may change the way PAD/CLI patients are treated.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.